Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Corporate and Financial Cytrx Corp. (CYTR)
For a non-revenue-generating, development-stage life science company, a strong balance sheet will always be a key concern. CytRx ended the second quarter of 2017 with $55 million in cash. Subsequent to the close of the second quarter, the NantCell transaction brought in an additional $13 million through their purchase of CytRx common shares at $1.10 per share, an approximately 92% premium to the Company's stock price at that time. The Company also restructured and paid down $10 million of its existing debt during the third quarter.
During 2017, CytRx has made significant strides in advancing its lead oncology asset aldoxorubicin from a late-stage clinical asset to a partnered, pre-New Drug Application (NDA) candidate in the U.S. In July 2017, CytRx announced a strategic licensing transaction with NantCell, Inc., for the global rights to aldoxorubicin. Dr. Patrick Soon-Shiong, the CEO and founder of NantCell, developed, obtained regulatory approval for, and commercialized Abraxane®, another albumin-mediated cytotoxic agent which currently generates approximately $1B in annual sales. CytRx believes that Dr. Soon-Shiong's track record and expertise with albumin-mediated agents will prove invaluable as NantCell works to obtain regulatory approval for aldoxorubicin, with the goal of commercialization thereafter.
"In addition to the initial indication of soft tissue sarcomas, NantCell is planning to develop aldoxorubicin in combination with immuno-oncology agents and cutting edge natural killer (NK) cell-based therapies in multiple tumor types, including breast and brain cancers," said David Haen, CytRx's Vice President of Business Development and Investor Relations. "NantCell is a true innovator in the field of oncology and brings a deep appreciation for the clinical benefit that aldoxorubicin can offer patients. We are confident that placing the asset in their hands will maximize both its future clinical and commercial potential."
CytRx has been actively working with the NantCell team to transition the aldoxorubicin program, including both completed and ongoing studies. Both teams are diligently working toward the preparation of the NDA for aldoxorubicin as a new treatment for soft tissue sarcomas, as well as getting additional clinical trials underway. CytRx looks forward to seeing aldoxorubicin enter NantCell-initiated clinical trials in the near future.
LADR™ Technology Platform and CytRx's Future Oncology Pipeline
CytRx's internal R&D activities at its expanded laboratory in Freiberg, Germany, are now focused on developing new drug candidates generated from its proprietary LADR™ (Linker Activated Drug Release) discovery platform.
Ongoing preclinical data is being generated for several LADR™-derived ultra-high potency compounds, and CytRx researchers have obtained partial and complete responses in a variety of solid tumor animal models to date. Additional in vivo efficacy and toxicology testing is underway, and CytRx's goal is to file one or more new patent applications during the fourth quarter of 2017. The Company also hopes to nominate the next LADR™ candidate for clinical development by the end of 2017 and to submit these important preclinical data for presentation at an upcoming scientific meeting in 2018. CytRx is extremely eager to move these programs forward and is taking great care to select the correct clinical candidates in order to optimally position these molecules for success once they enter clinical trials.
CytRx's strategy is to pursue a two-pronged approach to advancing its ultra-high potency LADR™ conjugates. Once a candidate is selected for clinical testing, the Company will conduct the necessary preclinical studies to enable an Investigational New Drug (IND) application filing, with the goal of taking the first LADR™-discovered, ultra-high potency conjugate into clinical trials during 2018. If the selected conjugate is successful in early-stage clinical studies although there can be no guarantee, CytRx hopes to seek Breakthrough Designation from the FDA. In parallel with internally advancing its LADR™-discovered conjugates, the Company also plans to explore pre-clinical strategic alliances with large pharmaceutical partners where a collaboration could demonstrate the utility of the LADR™ platform.
https://finance.yahoo.com/news/cytrx-corporation-provides-business-highlights-130000626.html
STRONG BUY ! GET MORE SHARES REVENUE UP!
$DRRX ALL INDICATORS POINTING OUT OPEN AT $1+
DURECT Corporation (DRRX): Hold Candidate With 126.44% Upside Potential
DURECT Corporation is maintained at an average hold rating by 2 stock analysts, and there are at least 0.84% of shares outstanding that are currently legally short sold. The shares went down by -56.28% in value last month. Year-to-date it plunged -35.07%. Analysts are turning out to be neutral than before, with 0 of analysts who cover DURECT Corporation (NASDAQ:DRRX) advice adding it to buy candidate list. Wall Street experts also assign a $1.97 price target on DURECT Corporation, pointing towards a 126.44% rally from current levels. The stock is trading for about -59.91% less than its 52-week high.
DURECT Corporation Reports -18.06% Sales Growth
DURECT Corporation (DRRX) remained successful in beating the consensus-estimated -$0.06 as it actually earned -$0.04 per share in its last reported financial results. Revenue, on the other hand, scored -18.06% growth from the previous quarter, coming up with $3.54 million.
https://postanalyst.com/2017/11/03/what-do-wall-street-analysts-think-of-durect-corporation-drrx-owens-minor-inc-omi/
BUY ALERT! $41.00 target price Brean Capital reaffirmed their buy rating on shares of $RPRX in a report issued. They currently have a $41.00 target price on the stock.
$DRRX ALL INDICATORS POINTING OUT OPEN AT $1+
Executed a patent purchase agreement with Indivior relevant to Indivior's RBP-7000, yielding DURECT a $12.5 million upfront payment, as well as a potential $5 million milestone payment and potential earn-out payments. Indivior submitted a NDA for RBP-7000 to the U.S. FDA on September 28, 2017.
Including the $12.5 million described above, total revenues were $20.7 million and net income was $6.1 million for the three months ended September 30, 2017 as compared to total revenues of $3.7 million and net loss of $8.8 million for the three months ended September 30, 2016.
At September 30, 2017, cash and investments were $41.8 million, compared to cash and investments of $25.2 million at December 31, 2016.
BUY ALERT=BUY-BUY-BUY NOW! Revenue UP looking $1.49 closing and Opening at $1.99
https://www.prnewswire.com/news-releases/durect-corporation-announces-third-quarter-2017-financial-results-and-provides-corporate-update-300547706.html
BUY ALERT Revenue UP looking $1.49 closing and Opening at $1.99
https://www.prnewswire.com/news-releases/durect-corporation-announces-third-quarter-2017-financial-results-and-provides-corporate-update-300547706.html
STRONG SELL=ITS FRAUD! WHY IN FINANCIAL STATEMENTS NEVER SHOWN THE MONEY WAS RECEIVED FROM THIS CONTRACTS = BECAUSE IS A FRAUD . IF YOU SEE ALL Q.1234 ALL YEAR COMPANY LOOS MONEY =WHY?
The Bon-Ton Stores, Inc. Brings World-Famous FAO Schwarz® Toy Brand to Nearly 200 Department Stores
Just in time for the holidays and here to stay year round, launch will be celebrated with ribbon cutting ceremonies, free gifts to the first 25 children who visit and a special #returntowonder photo contest
https://www.prnewswire.com/news-releases/the-bon-ton-stores-inc-brings-world-famous-fao-schwarz-toy-brand-to-nearly-200-department-stores-300544218.html
STRONG BUY ALERT- Share price will hit $5.90 a share=BONT continue make a profit in the 3q sells incensed my estimates $650 millions in sells 4q sells will go over $1 billion . Share price will hit $5.90 a share .
https://globenewswire.com/news-release/2017/11/02/1173277/0/en/The-Bon-Ton-Stores-Inc-to-Report-Third-Quarter-Fiscal-2017-Results.html
TIME TO BUY MORE -THANK YOU . CHRISTMAS SOON - WE WILL SEE $0.89 -$0.99 -$1.29
BUY-BUY-BUY WOW SO CHIP
$BONT BUY ALERT $$$$$ WE WILL REACH $1.29 TODAY
Repros Therapeutics (NASDAQ:RPRX) last issued its earnings results on Monday, The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.14.
BUY ALERT NEWS COMING ANY TIME
~ Blue ~' Why not shewing exec date when R/S will be executed ?
What is meaning ( subject to confirmation of the record date with Nasdaq.)
Please reply publiclly if you know as moderator ? Thank you ~ Blue ~
CytRx plans to implement the reverse stock split next week, subject to confirmation of the record date with Nasdaq.
SELL-SELL=SELL I SEE $0.15 BY MONDAY BEFORE R/S
FOR the proposal to be approved. 87,424,496 shares voted FOR the proposal, which constitutes a majority of the issued and outstanding shares. 42,039,394 shares voted against and 368,355 abstained.
FOR the proposal to be approved. 87,424,496 shares voted FOR the proposal, which constitutes a majority of the issued and outstanding shares. 42,039,394 shares voted against and 368,355 abstained.
BUY ALERT NEWS- Analyst’s mean target price for CYTX is $2.17
The EPS of Cytori Therapeutics, Inc. is strolling at -1.03. The company’s Market capitalization is $13.17M with the total Outstanding Shares of 209.67M.
Analyst’s mean target price for CYTX is $2.17 while analysts mean suggestion is 2.3.
http://www.stocknews.pro/2017/10/13/worth-watching-active-stocks-news-update-visa-inc-nyse-vfirst-bancorp-nyse-fbp-cytori-therapeutics-inc-nasdaq-cytx/
NO R/S =NO BC-DUE THAT FACT COPANY WAS SOLD FOR $346 MILLION
I BELIVE (CYTR) SHARES WILL DROP ONATHER 5 C BEFORE WILL GO UP
$ATOS -BUY BUY BUY WILL GET TO $0.89 TODAY =SHORTS YOU WILL EAT YOUR TANG Bullish
BUY-BUY-BUY LET DIRECTORS PAY DIFERENCE FROM THIER PACKETS Bullish
STRONG BUY -I am BUYING all this shares on marcket as mutch I can /
I do not sell my shares for $0.44 let Manigment sell it own shares and I will buy them.
All Directorrs must be imidiatly replased and jailed for the neket fraud/
I am colling General Sharholders Meeting to fyer this idiots.
STRONG BUY! Performance Review Of Atossa Genetics Inc., (NASDAQ: ATOS):
The stock has shown weekly performance of 73.02% and monthly performance stands at 97.16%. The stock has shown quarterly performance of 140.85% and a half-year performance stands at 34.59%.
http://www.tradingnewsnow.com/2017/10/26/notable-stocks-trending-alert-gerdau-s-a-nyse-ggb-atossa-genetics-inc-nasdaq-atos-ignyta-inc-nasdaq-rxdx-gannett-co-inc-nyse-gci/
NO R/S accourding to filling today
We have until November 7, 2017 to either regain compliance, or request additional time to regain compliance.
https://ih.advfn.com/p.php?pid=nmona&article=75944543#S107846_424B3_HTM_A004_V1
ImagesaladinsBy saladins on
STRONG BUY ! Shars price offerd $1.22 per share.
Our common stock is listed on The NASDAQ Capital Market under the symbol “ATOS.” On October 25, 2017, the last reported sales price of our common stock on The NASDAQ Capital Market was $1.22 per share.
https://ih.advfn.com/p.php?pid=nmona&article=75944543#S107846_424B3_HTM_A004_V1
NO R/S acourding to filling today
We have until November 7, 2017 to either regain compliance, or request additional time to regain compliance.
https://ih.advfn.com/p.php?pid=nmona&article=75944543#S107846_424B3_HTM_A004_V1
Time to BUY $ATOS = NO R/S shares will gong UP- investers just took profits, after $1.90 run /STRONG BUY!
STRONG BUY ALERT CLOSING AT $1.47
STRONG BUY ALERT CLOSING AT $1.47
NO R/S NEED - America Announces Adjournment of Special Meeting of Stockholders EXSTENTION GRANTED
https://finance.yahoo.com/news/amedica-receives-positive-nasdaq-listing-130000508.html
BUY ALERT! WE GOND FLY $$$$$$$
STRONG BUY ALERT looking $1.10 closing
Time to Buy DRRX its will go back to $1.29 any time
Time to Buy =revenue incensed 47% last Q1
$NEOT BUY ALERT NEWS ! Amphora® iQualified Infectious Disease Product (QIDP) by the U.S. Food & Drug Administration for two separate indications: the prevention of urogenital gonorrhea infection in women, and for the reduction of reoccurrence of bacterial vaginosis.
$NEOT, BUY BUY BUY !Evofem Biosciences Ink Merger Deal to Create Women’s Health Company
http://crweworld.com/article/news-provided-by-globenewswire/157161/neothetics-inc-and-evofem-biosciences-inc-announce-merger-agreement-to-create-womens-health-company